Clinical Trial Update: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ATGC-110 botulinum toxin with Xeomin for moderate to severe glabellar frown lines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines

Drugs mentioned

• ATGC-110 (botulinum toxin)
• XEOMIN (INCOBOTULINUMTOXINA)

Snippet

Sponsor: ATGC Co., Ltd. | Conditions: Glabellar Frown Lines | Phase 3 | Status: UNKNOWN